KLRK1 and hematologic disorder: Advances in cellular engineering, precision CAR design, NKG2DLs signal enhancement, and synergistic combinations will be critical to maximizing the therapeutic potential of NKG2D CAR-T or CAR-NK cells across solid and hematologic malignancies.